First-line immunotherapy does not improve survival in metastatic lung cancer

Single or combination first-line immunotherapy does not significantly extend survival compared with chemotherapy in metastatic non small-cell lung carcinoma, trial results have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research